Shandong Keyuan Pharmaceutical Co. Ltd. A (301281.SZ) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · China · ISIN CNE1000061V8

Price
39.60 CNY
Market cap
4.29 bn CNY
P/E (2025)
259.06
P/S (2025)
10.77
Dividend yield
0.13 %
Net margin
4.16 %
Return on equity (ROE)
1.22 %
Return on assets (ROA)
0.98 %

Shandong Keyuan Pharmaceutical Co. Ltd. A financials

Fiscal year20242025
Revenue463.72 m CNY398.23 m CNY
Gross profit205.28 m CNY212.80 m CNY
Operating income61.62 m CNY44.58 m CNY
EBIT65.75 m CNY16.79 m CNY
Net income60.45 m CNY16.55 m CNY
Diluted EPS – continuing operations0.56 CNY0.15 CNY

Full history since 2021, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Shandong Keyuan Pharmaceutical Co. Ltd. A

Shandong Keyuan Pharmaceutical Co., Ltd. is involved in the research and development, manufacture, and marketing of chemical raw materials and their preparations. It offers gliclazide; metformin hydrochloride; isosorbide mononitrate; isosorbide dinitrate; lansoprazole; mecobalamin; ropivacaine hydrochloride; isoflurane; fluoxetine hydrochloride; clarithromycin L-lactate; chlorpheniramine maleate; esmolol hydrochloride; isoproterenol hydrochloride; nicotinamide-tinidazole; aminolevulinate; nisoldipine; qupibutu; propafenone hydrochloride; potassium diclofenac; chlorzoxazone; esomeprazole sodium; palonosetron hydrochloride; idalafeng; piroxicam; phenylephrine; vildagliptin; parecoxib sodium; and ruxolitinib hydrochloride. Shandong Keyuan Pharmaceutical Co., Ltd. was founded in 2004 and is headquartered in Jinan, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.